• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

潜在抑制剂可阻断 ACE2 与带有突变的 SARS-CoV-2 刺突蛋白结合。

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.

机构信息

Department of Otolaryngology, Chang Gung Memorial Hospital, Chiayi, Taiwan; Faculty of Medicine, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.

Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.

出版信息

Biomed Pharmacother. 2022 May;149:112802. doi: 10.1016/j.biopha.2022.112802. Epub 2022 Mar 9.

DOI:10.1016/j.biopha.2022.112802
PMID:35279013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8906167/
Abstract

At the time of writing, more than 440 million confirmed coronavirus disease 2019 (COVID-19) cases and more than 5.97 million COVID-19 deaths worldwide have been reported by the World Health Organization since the start of the outbreak of the pandemic in Wuhan, China. During the COVID-19 pandemic, many variants of SARS-CoV-2 have arisen because of high mutation rates. N501Y, E484K, K417N, K417T, L452R and T478K in the receptor binding domain (RBD) region may increase the infectivity in several variants of SARS-CoV-2. In this study, we discovered that GB-1, developed from Chiehyuan herbal formula which obtained from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, can inhibit the binding between ACE2 and RBD with Wuhan type, K417N-E484K-N501Y and L452R-T478K mutation. In addition, GB-1 inhibited the binding between ACE2 and RBD with a single mutation (E484K or N501Y), except the K417N mutation. In the compositions of GB-1, glycyrrhizic acid can inhibit the binding between ACE2 and RBD with Wuhan type, except K417N-E484K-N501Y mutation. Our results suggest that GB-1 could be a potential candidate for the prophylaxis of different variants of SARS-CoV-2 infection because of its inhibition of binding between ACE2 and RBD with different mutations (L452R-T478K, K417N-E484K-N501Y, N501Y or E484K).

摘要

截至撰写本文时，自中国武汉爆发大流行以来，世界卫生组织已报告全球超过 4.4 亿例 2019 年冠状病毒病（COVID-19）确诊病例和超过 597 万例 COVID-19 死亡病例。在 COVID-19 大流行期间，由于高突变率，SARS-CoV-2 的许多变体已经出现。受体结合域（RBD）区域中的 N501Y、E484K、K417N、K417T、L452R 和 T478K 可能会增加几种 SARS-CoV-2 变体的传染性。在这项研究中，我们发现，从嘉义朴子培天宫天上圣母获得的百草园草药配方开发的 GB-1 可以抑制武汉型、K417N-E484K-N501Y 和 L452R-T478K 突变的 ACE2 和 RBD 之间的结合。此外，GB-1 除 K417N 突变外，还抑制了 ACE2 和 RBD 之间具有单个突变（E484K 或 N501Y）的结合。在 GB-1 的成分中，甘草酸可以抑制武汉型 ACE2 和 RBD 之间的结合，除了 K417N-E484K-N501Y 突变。我们的结果表明，GB-1 可能是预防不同 SARS-CoV-2 变异感染的潜在候选药物，因为它可以抑制不同突变（L452R-T478K、K417N-E484K-N501Y、N501Y 或 E484K）的 ACE2 和 RBD 之间的结合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/48d6821f0c18/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/f3d124b77fe6/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/507a04917951/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/15c679c3d94a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/e4b3063415e5/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/b376f9a55710/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/95a9032a9746/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/36f7c2c1ead4/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/7a1ecfc91641/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/c01dbddcb2d2/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/d2cb635e3795/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/48d6821f0c18/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/f3d124b77fe6/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/507a04917951/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/15c679c3d94a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/e4b3063415e5/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/b376f9a55710/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/95a9032a9746/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/36f7c2c1ead4/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/7a1ecfc91641/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/c01dbddcb2d2/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/d2cb635e3795/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c727/8906167/48d6821f0c18/gr10_lrg.jpg

相似文献

1
Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.潜在抑制剂可阻断 ACE2 与带有突变的 SARS-CoV-2 刺突蛋白结合。
Biomed Pharmacother. 2022 May;149:112802. doi: 10.1016/j.biopha.2022.112802. Epub 2022 Mar 9.
2
GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.GB-2阻断ACE2与新型冠状病毒野生型及刺突蛋白突变体之间的相互作用。
Biomed Pharmacother. 2021 Oct;142:112011. doi: 10.1016/j.biopha.2021.112011. Epub 2021 Aug 5.
3
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的新变种及针对冠状病毒（COVID-19）的新型疗法
4
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.常见突变对 SARS-CoV-2 刺突 RBD 及其配体人 ACE2 受体结合亲和力和动力学的影响。
Elife. 2021 Aug 26;10:e70658. doi: 10.7554/eLife.70658.
5
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.SARS-CoV-2 新变体的传染性更高与 K417N/T、E484K 和 N501Y 突变有关：来自结构数据的见解。
J Cell Physiol. 2021 Oct;236(10):7045-7057. doi: 10.1002/jcp.30367. Epub 2021 Mar 23.
6
Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).解析 SARS-CoV-2 刺突突变体与 ACE2（血管紧张素转化酶 2）的分子相互作用。
J Biomol Struct Dyn. 2022;40(23):12760-12771. doi: 10.1080/07391102.2021.1975569. Epub 2021 Sep 8.
7
Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.在下午3点的情境下，对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白/血管紧张素转换酶2（ACE2）蛋白质-蛋白质相互作用进行建模，以预测新的刺突蛋白变体与ACE2以及与ACE2结构相关的新型人类蛋白质靶点的结合亲和力，用于新冠疫情应对。
EPMA J. 2022 Jan 6;13(1):149-175. doi: 10.1007/s13167-021-00267-w. eCollection 2022 Mar.
8
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.疫苗逃逸和快速突变在英国、美国、新加坡、西班牙、印度和其他受 COVID-19 肆虐的国家。
Genomics. 2021 Jul;113(4):2158-2170. doi: 10.1016/j.ygeno.2021.05.006. Epub 2021 May 15.
9
In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.利用计算机模拟方法研究新型英国（B.1.1.7）和南非（501Y.V2）SARS-CoV-2 变异株，重点关注 ACE2-刺突 RBD 界面。
Int J Mol Sci. 2021 Feb 8;22(4):1695. doi: 10.3390/ijms22041695.
10
The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution.赤西园中药口腔防护液抗新型冠状病毒肺炎的作用及机制
Heliyon. 2023 Jul 3;9(7):e17701. doi: 10.1016/j.heliyon.2023.e17701. eCollection 2023 Jul.

引用本文的文献

1
The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants.GB-2、（+）-儿茶素、茶黄素和茶黄素 3-没食子酸酯对 ACE2 与 SARS-CoV-2 EG.5.1 和 HV.1 变异株相互作用的抑制作用。
Int J Mol Sci. 2024 Aug 31;25(17):9498. doi: 10.3390/ijms25179498.
2
Rational Design Problematics of Peptide Nucleic Acids as SARS-CoV-2 Inhibitors.作为新型冠状病毒 2 型抑制剂的肽核酸的合理设计问题
ACS Omega. 2024 Jul 16;9(30):33000-33010. doi: 10.1021/acsomega.4c04023. eCollection 2024 Jul 30.
3
Research on the global trends of COVID-19 associated acute kidney injury: a bibliometric analysis.

本文引用的文献

1
Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 Viruses.甘草次酸烟酰胺衍生物的合成及抗 HIV-1 假病毒和 SARS-CoV-2 病毒的体外活性研究。
Molecules. 2022 Jan 4;27(1):295. doi: 10.3390/molecules27010295.
2
Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment.甘草酸通过阻断刺突蛋白介导的细胞附着来抑制新型冠状病毒2感染。
Molecules. 2021 Oct 9;26(20):6090. doi: 10.3390/molecules26206090.
3
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.
COVID-19 相关急性肾损伤的全球趋势研究：文献计量分析。
Ren Fail. 2024 Dec;46(1):2338484. doi: 10.1080/0886022X.2024.2338484. Epub 2024 Jun 4.
4
Unraveling the binding mechanisms of SARS-CoV-2 variants through molecular simulations.通过分子模拟揭示新冠病毒变异株的结合机制。
Heliyon. 2024 Feb 29;10(5):e27193. doi: 10.1016/j.heliyon.2024.e27193. eCollection 2024 Mar 15.
5
The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution.赤西园中药口腔防护液抗新型冠状病毒肺炎的作用及机制
Heliyon. 2023 Jul 3;9(7):e17701. doi: 10.1016/j.heliyon.2023.e17701. eCollection 2023 Jul.
6
Nutrients, herbal bioactive derivatives and commensal microbiota as tools to lower the risk of SARS-CoV-2 infection.营养物质、草药生物活性衍生物和共生微生物群作为降低新型冠状病毒感染风险的工具。
Front Nutr. 2023 Jun 1;10:1152254. doi: 10.3389/fnut.2023.1152254. eCollection 2023.
7
Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment.甘草酸和乳香酸，金营养保健品：针对轻度至中度 COVID-19 的多靶点治疗和预防 COVID 后认知障碍。
Inflammopharmacology. 2022 Dec;30(6):1977-1992. doi: 10.1007/s10787-022-01062-3. Epub 2022 Sep 22.
广谱中和抗体对新兴 SARS-CoV-2 变异株的作用
Front Immunol. 2021 Sep 27;12:752003. doi: 10.3389/fimmu.2021.752003. eCollection 2021.
4
SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response.SARS-CoV-2 病毒-宿主相互作用：目前可用的结构以及变异体出现对感染性和免疫反应的影响。
Int J Mol Sci. 2021 Oct 7;22(19):10836. doi: 10.3390/ijms221910836.
5
SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关注变异株德尔塔：对2019冠状病毒病（COVID-19）防控的巨大挑战。
Signal Transduct Target Ther. 2021 Sep 27;6(1):349. doi: 10.1038/s41392-021-00767-1.
6
The biological and clinical significance of emerging SARS-CoV-2 variants.新兴 SARS-CoV-2 变体的生物学和临床意义。
Nat Rev Genet. 2021 Dec;22(12):757-773. doi: 10.1038/s41576-021-00408-x. Epub 2021 Sep 17.
7
Significant Inactivation of SARS-CoV-2 In Vitro by a Green Tea Catechin, a Catechin-Derivative, and Black Tea Galloylated Theaflavins.绿茶儿茶素、儿茶素衍生物和红茶没食子酰化茶黄素体外有效灭活 SARS-CoV-2。
Molecules. 2021 Jun 11;26(12):3572. doi: 10.3390/molecules26123572.
8
Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?甘草的抗病毒活性能帮助对抗 COVID-19 感染吗？
Biomolecules. 2021 Jun 8;11(6):855. doi: 10.3390/biom11060855.
9
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab .SARS-CoV-2 的 501Y.V2 和 501Y.V3 变体与巴美洛单抗失去结合能力。
MAbs. 2021 Jan-Dec;13(1):1919285. doi: 10.1080/19420862.2021.1919285.
10
Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants.实验证据表明，快速传播的 SARS-CoV-2 变异株增强了受体结合能力。
J Mol Biol. 2021 Jul 23;433(15):167058. doi: 10.1016/j.jmb.2021.167058. Epub 2021 May 21.